Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. I...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.982155/full |
| _version_ | 1818020748676038656 |
|---|---|
| author | Daniel Leung Xiaofeng Mu Jaime S. Rosa Duque Samuel M. S. Cheng Manni Wang Wenyue Zhang Yanmei Zhang Issan Y. S. Tam Toby S. S. Lee Jennifer H. Y. Lam Sau Man Chan Cheuk Hei Cheang Yuet Chung Howard H. W. Wong Amos M. T. Lee Wing Yan Li Sara Chaothai Leo C. H. Tsang Gilbert T. Chua Kai-Ning Cheong Elaine Y. L. Au Janette S. Y. Kwok Koon Wing Chan Patrick C. Y. Chong Pamela P. W. Lee Marco H. K. Ho Tsz Leung Lee Wenwei Tu Malik Peiris Malik Peiris Yu Lung Lau |
| author_facet | Daniel Leung Xiaofeng Mu Jaime S. Rosa Duque Samuel M. S. Cheng Manni Wang Wenyue Zhang Yanmei Zhang Issan Y. S. Tam Toby S. S. Lee Jennifer H. Y. Lam Sau Man Chan Cheuk Hei Cheang Yuet Chung Howard H. W. Wong Amos M. T. Lee Wing Yan Li Sara Chaothai Leo C. H. Tsang Gilbert T. Chua Kai-Ning Cheong Elaine Y. L. Au Janette S. Y. Kwok Koon Wing Chan Patrick C. Y. Chong Pamela P. W. Lee Marco H. K. Ho Tsz Leung Lee Wenwei Tu Malik Peiris Malik Peiris Yu Lung Lau |
| author_sort | Daniel Leung |
| collection | DOAJ |
| description | Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity. |
| first_indexed | 2024-04-14T08:09:45Z |
| format | Article |
| id | doaj.art-40439ee79362418ba1ea1faa97dea241 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-14T08:09:45Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-40439ee79362418ba1ea1faa97dea2412022-12-22T02:04:36ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.982155982155Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunityDaniel Leung0Xiaofeng Mu1Jaime S. Rosa Duque2Samuel M. S. Cheng3Manni Wang4Wenyue Zhang5Yanmei Zhang6Issan Y. S. Tam7Toby S. S. Lee8Jennifer H. Y. Lam9Sau Man Chan10Cheuk Hei Cheang11Yuet Chung12Howard H. W. Wong13Amos M. T. Lee14Wing Yan Li15Sara Chaothai16Leo C. H. Tsang17Gilbert T. Chua18Kai-Ning Cheong19Elaine Y. L. Au20Janette S. Y. Kwok21Koon Wing Chan22Patrick C. Y. Chong23Pamela P. W. Lee24Marco H. K. Ho25Tsz Leung Lee26Wenwei Tu27Malik Peiris28Malik Peiris29Yu Lung Lau30Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaHong Kong Children’s Hospital, Hong Kong, Hong Kong SAR, ChinaDivision of Clinical Immunology, Department of Pathology, Queen Mary Hospital, Hong Kong, Hong Kong SAR, ChinaDivision of Transplantation and Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaVirtus Medical, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaVirtus Medical, Hong Kong, Hong Kong SAR, ChinaHong Kong Children’s Hospital, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaSchool of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaCentre for Immunology and Infection C2i, Hong Kong, Hong Kong SAR, ChinaDepartment of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, ChinaOur study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.https://www.frontiersin.org/articles/10.3389/fimmu.2022.982155/fullBNT162b2CoronaVacCOVID-19inborn errors of immunityvaccine |
| spellingShingle | Daniel Leung Xiaofeng Mu Jaime S. Rosa Duque Samuel M. S. Cheng Manni Wang Wenyue Zhang Yanmei Zhang Issan Y. S. Tam Toby S. S. Lee Jennifer H. Y. Lam Sau Man Chan Cheuk Hei Cheang Yuet Chung Howard H. W. Wong Amos M. T. Lee Wing Yan Li Sara Chaothai Leo C. H. Tsang Gilbert T. Chua Kai-Ning Cheong Elaine Y. L. Au Janette S. Y. Kwok Koon Wing Chan Patrick C. Y. Chong Pamela P. W. Lee Marco H. K. Ho Tsz Leung Lee Wenwei Tu Malik Peiris Malik Peiris Yu Lung Lau Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity Frontiers in Immunology BNT162b2 CoronaVac COVID-19 inborn errors of immunity vaccine |
| title | Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity |
| title_full | Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity |
| title_fullStr | Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity |
| title_full_unstemmed | Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity |
| title_short | Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity |
| title_sort | safety and immunogenicity of 3 doses of bnt162b2 and coronavac in children and adults with inborn errors of immunity |
| topic | BNT162b2 CoronaVac COVID-19 inborn errors of immunity vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.982155/full |
| work_keys_str_mv | AT danielleung safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT xiaofengmu safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT jaimesrosaduque safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT samuelmscheng safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT manniwang safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT wenyuezhang safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT yanmeizhang safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT issanystam safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT tobysslee safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT jenniferhylam safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT saumanchan safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT cheukheicheang safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT yuetchung safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT howardhwwong safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT amosmtlee safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT wingyanli safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT sarachaothai safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT leochtsang safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT gilberttchua safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT kainingcheong safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT elaineylau safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT janettesykwok safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT koonwingchan safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT patrickcychong safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT pamelapwlee safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT marcohkho safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT tszleunglee safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT wenweitu safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT malikpeiris safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT malikpeiris safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity AT yulunglau safetyandimmunogenicityof3dosesofbnt162b2andcoronavacinchildrenandadultswithinbornerrorsofimmunity |